New drug cocktail targets tough colorectal cancers
NCT ID NCT06369259
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of three drugs—avutometinib, defactinib, and cetuximab—can help control advanced colorectal cancer that has stopped responding to standard anti-EGFR treatment. About 33 participants will receive the drugs orally and intravenously. The main goal is to check safety and see if the cancer shrinks or stabilizes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avutometinib, defactinib, and cetuximab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced colorectal cancer that no longer responds to standard anti-EGFR therapy.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The drug combination may cause side effects and may not control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77807, United States
Contact Email: •••••@•••••
Contact